Navigation Links
ThromboGenics N.V.: Business Update

LEUVEN, Belgium, November 6 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update for the nine months period ended 30 September 2008.

Patrik De Haes, CEO of ThromboGenics, commenting on today's announcement, said: "ThromboGenics' clinical development programs continue to progress as anticipated. We are now working hard to prepare for the Phase III clinical program for microplasmin in eye disease following a successful End of Phase II Meeting with the FDA. The recent positive results from our Phase II trials with microplasmin have given us further confidence that this product has the potential to make a real difference in the field of eye disease. We are also developing a good working relationship with our strategic partner Roche as the clinical development of our new anti-cancer antibody TB-403 continues to progress. With our solid financial situation, I believe that ThromboGenics will deliver further important corporate milestones over the next 12 to 18 months as we continue to work to build value for our shareholders."
Financial Update

- In the first nine months of 2008, ThromboGenics achieved

revenues of EUR 30.3 million, mainly from out-licensing activities.

Operating expenses were EUR 17.0 million during this nine month period,

the majority of which were due to R&D expenses related to an increasing

number of clinical development programs.

- As of 30 September 2008, ThromboGenics had EUR 60.9 million

in cash and cash equivalents. This compares to EUR 50.6 million on 30

September 2007 and EUR 40.1 million on 31 December 2007. ThromboGenics

believes that this level of funding will allow it to complete the Phase

III program for the initial indication for microplasmin in eye disease.

- In late July, ThromboG

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
(Date:9/16/2014)... BELLINGHAM, Washington, USA (PRWEB) September 16, 2014 ... how to create the features that we desire in ... Technology Center at Montana State University. “As we explore ... , Some of those lessons were presented in San ... Nature of Light: Light in Nature ” chaired by ...
(Date:9/16/2014)... Sept. 16, 2014  Biocom, the association representing the ... recognizes the 9 th Annual National Health Information ... IT technologies in improving our health care system. ... one of the world,s most vibrant hubs for health ... health applications to genomic testing to remote patient monitoring," ...
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
(Date:9/16/2014)... N.Y. , Sept. 16, 2014  Donald Fresne, President ... appointment of Stephan Vagner , PhD to its Scientific ... University of Toulouse, France , performed research ... , and at Inserm, the French institute of health ... and works both at the Curie Institute, Orsay, ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2
... 2011 Masimo (NASDAQ: MASI ) today announced that ... Company 31st Annual Growth Stock Conference at the Four Seasons Hotel ...  A live audiocast of the presentation will be available on the ... will be available following the live presentation. ...
... developed a method for creating single-crystal arrays of the ... a replacement for silicon in high-performance computers and electronics. ... featured on the cover of the June issue of ... of carbon that was first fabricated in 2004. Single-crystal ...
... Genentech and Novartis have the best image among oncologists ... research consultancy that recently completed its 2011 MSImage study. ... equity and R&D attributes to determine which measures drive ... marketplace. Amgen, Sanofi-aventis and Eli Lilly/ImClone ...
Cached Biology Technology:Masimo to Present at William Blair & Company 31st Annual Growth Stock Conference 2University of Houston develops method for creating single-crystal arrays of graphene 2Genentech and Novartis Remain Image Leaders in Oncology and Hematology 2Genentech and Novartis Remain Image Leaders in Oncology and Hematology 3
(Date:9/16/2014)... 17, 2014)The North American Menopause Society (NAMS) has ... care of midlife womenon everything from hot flashes ... American Menopause Society Recommendations for Clinical Care of ... Society,s journal Menopause . This is the ... care of midlife women freely available to all ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... "Socioeconomic Conditions Along the World,s Tropical Coasts: 2008," ... coral reefs in 27 tropical nations and points to ... recommendations as a significant barrier to coral reef protection. ... "Status of Coral Reefs of the World: 2008" from ...
... --- Research by a Michigan State University chemist could ... developing protein-based drugs that are key to treating a ... Proteins used in drug manufacture and research often are ... one-cell bacteria. That protein tends to collect into what ...
... molecules i.e. substances which can be stimulated to ... research and medical diagnosis. Fluorescence can be used for ... to locate proteins in cells and tissues, to follow ... of cells. Of particular importance is the combination of ...
Cached Biology News:First-ever socioeconomic study on coral reefs points to challenges of coastal resource management 2First-ever socioeconomic study on coral reefs points to challenges of coastal resource management 3Novel technique for fluorescence tomography of tumors in living animals 2
... identification Service includes 1. Scanning of ... 3. High-sensitive tryptic in-gel digestion and ... for MALDI-MS 5. Acquisition of PMF ... (Bruker ultraflex TOF/TOF) 6. Acquisition of ...
Each Yeast-GFP clone represents an individual S. cerevisiae strain containing an open reading frame with a C-terminal Aequorea Victoria GFP (S65T) fusion tag....
... number is a new product number, ... number. If showing no availability yet, ... number (R4276) or contact customer service ... (expanded surface, easy grip) ...
... stored within neurons in vesicles called ... the synaptic bouton. Synaptosomes may ... from other cellular debris. Abnormalites in ... many pathological condtions. Conditions of ...
Biology Products: